Patients eligible to receive Takeda’s Exkivity (mobocertinib) have a rare form of lung cancer that cannot be removed by surgery
News
New research suggests women less likely to receive support for cardiogenic shock
Research analysed differences in treatment and survival between women and men with a heart attack and cardiogenic shock
Finalists announced for the 2022 International Clinical Researcher of the Year
With the significant increase in entries this year, the competition to name the finalists proved incredibly tough. The International Clinical Researcher judging panel, however, have made their decisions and the finalists have now been announced.
AstraZenca’s antibody cocktail Evusheld receives MHRA authorisation
Approval is significant as waning restrictions present significant threats to many immunocompromised people across the UK
Scientists identify two more hybrid variants alongside Deltacron
The hybrid of Delta and Omicron, known as ‘Deltacron’, has been identified in France, Denmark and the Netherlands
Waiting game: a record 6.1 million NHS patients are currently waiting for non-urgent treatment
The NHS has not met the 18-week target for people to receive planned treatment in England since February 2016
Omicron BA.2 variant triggers COVID-19 surge in England
The sub-variant combines mutations from both Omicron and Delta
Severe COVID-19 linked to risk of mental health effects
Patients who were bedridden for seven days or longer were at increased risk of depression and anxiety over the study period
NICE to improve diagnosis for foetal alcohol spectrum disorder
Better treatment for conditions experienced by individuals who were exposed to alcohol before birth
NHS mental health referrals has reached record high
COVID-19 has highlighted another significant widespread problem – the mental health pandemic
Bill & Melinda Gates Foundation launch initiative for future pandemics
The initiative will catalyse discovery and early development of antiviral medicines for future pandemics
COVID-19 infections seeing spike across UK
In the coming months, an additional vaccine booster will be offered to those over 75, care home residents and to those over 12 who are most vulnerable
State-of-the-art R&D facilities to be developed in Oxford city centre
Site will include creating space for student accommodation, offices, retail outlets and restaurants
Abivax reports promising rheumatoid arthritis results
Treatment demonstrated a good safety profile in the overall patient population during the 12-week induction phase
Waiting times for cancer referrals highest on record
93% of people suspected by GPs to have cancer should be seen by a specialist within two weeks but this has fallen to just 75%
